Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.44 |
| ▸ | DHFR | P00374 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065933 | 1.00 | NPC1 (0.50) | NPC1KDM4EGAAHSD17B10FGFR1 | |
| SCHEMBL4463005 | 0.80 | HCAR2 (0.42) | DHFRPIK3CAHCAR2 | |
| SCHEMBL4608258 | 0.80 | DHFR (0.46) | HSD17B10FGFR1DHFR | |
| SCHEMBL29528815 | 0.76 | DHFR (0.39) | FGFR1DHFRPIK3CA | |
| SCHEMBL4457723 | 0.75 | HCAR2 (0.43) | GAADHFRPIK3CAHCAR2SMN1; SMN2 | |
| SCHEMBL28814166 | 0.75 | PIK3CA (0.37) | FGFR1DHFRPIK3CASRC | |
| SCHEMBL4464801 | 0.73 | DHFR (0.42) | FGFR1DHFRSRC | |
| SCHEMBL28664537 | 0.73 | MKNK1 (0.40) | GAADHFRPIK3CAHCAR2SMN1; SMN2 | |
| SCHEMBL4984247 | 0.71 | CDK2 (0.53) | NPC1KDM4EGAAHSD17B10L3MBTL1 | |
| SCHEMBL28814284 | 0.71 | PIK3CA (0.35) | DHFRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427681-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-23 | — | — | US | claimed |
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| CN-118307674-A | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-115448910-B | Pyridazine derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-110785187-B | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-115448910-A | Pyridazine derivative inhibitor, and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-114920840-A | Antibody molecules against PD-L1 and uses thereof | 诺华股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-111757878-A | Pyridazine derivative inhibitor, and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2020-10-09 | — | — | CN | disclosed |
| CN-109843903-A | CYCLIC DINUCLEOTIDE COMPOUNDS | 勃林格殷格翰国际有限公司 | 2019-06-04 | — | — | CN | disclosed |
| US-8859574-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2014-10-14 | — | — | US | disclosed |
| CN-102112467-B | Pyrimidine derivative as kinase inhibitors | IRM LLC | 2014-04-30 | — | — | CN | disclosed |
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2013-11-21 | — | — | US | disclosed |
| WO-2010002655-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-01-07 | — | — | WO | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009013545-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310361-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IGF1R, IRS1, IP6K1 | NPC1 3518/4885KDM4E 1272/4885GAA 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.